2014
DOI: 10.1016/j.bbalip.2013.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Second generation S1P pathway modulators: Research strategies and clinical developments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
118
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 114 publications
(122 citation statements)
references
References 184 publications
4
118
0
Order By: Relevance
“…However, the metabolism of 2-hydroxyhexadecanal is unclear and is the subject of this study. (b) [11, H]PHS prepared in this study and [4, ARTICLE When the pAN9 plasmid, which encoded the 3xFLAG-tagged DPL1 gene under the control of the GAPDH promoter, was introduced into the Ddpl1 cells, C15 and C17 PC levels increased greatly, even when compared with the wild-type control ( Supplementary Fig. 3).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…However, the metabolism of 2-hydroxyhexadecanal is unclear and is the subject of this study. (b) [11, H]PHS prepared in this study and [4, ARTICLE When the pAN9 plasmid, which encoded the 3xFLAG-tagged DPL1 gene under the control of the GAPDH promoter, was introduced into the Ddpl1 cells, C15 and C17 PC levels increased greatly, even when compared with the wild-type control ( Supplementary Fig. 3).…”
Section: Resultsmentioning
confidence: 99%
“…The metabolism of PHS is currently unknown mainly due to the lack of commercially available radioactive PHS. Therefore, we prepared radiolabelled PHS ( [11, H]PHS) from [9, H]palmitic acid by metabolic conversion in yeast, followed by purification. The prepared [ 3 H]PHS presented as a single band that migrated to a position identical to a cold PHS standard on thin-layer chromatography (TLC; Fig.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…We therefore validated the therapeutic viability of targeting either signaling pathway, using medications that are either clinically available (ETN, an anti-TNF medication) or in clinical trials (S1P receptor antagonists) (19 Table 3). However, both interventions successfully reverse the STZ-augmented tone in HFD mice, normalizing it in both mesenteric and olfactory arteries to the level of ETN-or JTE013-treated NC controls (Fig.…”
Section: Hfd/stz Does Not Affect Pe Responses or Passive Diameters Inmentioning
confidence: 99%